Existing antiviral vaccines

La innovación de las vacunas ha permitido uno de los mayores avances en la historia de la salud pública. La primera de las vacunas han sido las vacunas antivirales, en particular la vacuna contra la viruela que fue desarrollada por primera vez por Edward Jenner en 1796. Este artículo revisará la vacunación para las siguientes enfermedades virales: sarampión, paperas, rubéola, polio, hepatitis A, hepatitis B , influenza, rotavirus, rabia, viruela del simio, viruela, encefalitis japonesa y fiebre amarilla.The innovation of vaccines has allowed for one of the greatest advancements in the history of public health. The first of the vaccines have been the antiviral vaccines, in particular the smallpox vaccine that was first developed by Edward Jenner in 1796. This article will review vaccination for the following viral diseases: measles, mumps, rubella, polio, hepatitis A, hepatitis B, influenza, rotavirus, rabies, monkeypox, smallpox, Japanese encephalitis, and yellow fever

HIV vaccines under study

La infección por el virus de la inmunodeficiencia humana (VIH) es una epidemia mundial, con más de 42 millones de personas infectadas actualmente. Desde el descubrimiento del VIH como agente causante del síndrome de inmunodeficiencia adquirida (SIDA), se han creado muchas vacunas potenciales. La primera de estas vacunas presentó resultados decepcionantes; sin embargo, eso no ha disuadido a los investigadores de continuar desarrollando más vacunas potenciales contra el VIH. Este artículo revisará los diversos candidatos a vacunas contra el VIH actualmente en estudio.Human immunodeficiency virus (HIV) infection is a worldwide epidemic, with over 42 million people currently infected. Since the discovery of HIV as the causative agent of the acquired immune deficiency syndrome (AIDS), many potential vaccines have been created. The first of these vaccines presented disappointing results; however, that has not deterred researchers from continuing to develop more potential HIV vaccines. This article will review the various current HIV vaccine candidates under study

Viremia in acute herpes zoster

A phase 2 trial was conducted to evaluate the efficacy of a topical antiviral, sorivudine, as an adjuvant to valacyclovir for the treatment of acute herpes zoster. In this randomized, placebo-controlled, double-blind trial, 25 patients were treated with either sorivudine or placebo cream. All patients began 7 days of valacyclovir treatment on day 3. Zoster lesion swab samples and samples of peripheral blood mononuclear cells were collected periodically throughout the study and were analyzed for varicella-zoster virus (VZV) DNA by use of both qualitative and real-time polymerase chain reaction. Serum samples collected periodically throughout the study were analyzed for VZV DNA by use of real-time polymerase chain reaction. VZV DNA was detected in all 3 sample types, and the number of viral copies correlated with the progression of herpes zoster. No statistically significant differences were seen between the placebo- and sorivudine-treated groups with respect to clinical characteristics or laboratory test results. The detection of VZV DNA in the serum and peripheral blood mononuclear cells of all 25 zoster patients documents that viremia is a common manifestation of herpes zoster. Sorivudine cream appears to be a safe and well-tolerated adjuvant therapy; however, further phase 2 studies are needed to determine its clinical efficacy for the treatment of herpes zoster. Trials registration. ClinicalTrials.gov identifier: NCT00652184